

REMARKS

Claims 20-25 are cancelled. New claim 26 has been added, support for the amendment can be found in the specification as originally filed. No new matter has been added.

CLAIMS 21 AND 23 ARE REJECTED UNDER 35 USC 112 FIRST PARAGRAPH

Claims 21 and 23 stand rejected under 35 USC 112 first paragraph as allegedly failing to comply with the written description requirement.

Claims 21 and 23 are cancelled. New claim 26 relates to a method of reducing, disrupting, dissolving or inhibiting amyloid fibrils comprising administering a therapeutically effective amount of the composition formerly claimed in claim 20. Claim 8, as originally filed, provides written support for new claim 26 as does page 4 of the specification. Additionally, the specification, in studies 1-5 and figures 1-5 presents data which support s the dose dependent dissolution, reduction, disruption and inhibition of the A β 1-40 and 1-42 fibrils of Alzheimer's disease.

CLAIMS 20 - 23 ARE REJECTED UNDER 35 USC 103(a)

Claims 20 - 23 stand rejected under 35 USC 103(a) as allegedly obvious in view of Hastings, Hsia and Zhou. Claims 20 -23 are cancelled. New claim 26 relates to a method of reducing, disrupting, dissolving or inhibiting amyloid fibrils comprising administering a therapeutically effective amount of a composition formerly claimed in claim 20.

Applicant submits that neither Hastings, Hsia nor Zhou teach a method of reducing, disrupting, dissolving or inhibiting amyloid fibrils as claimed in new claim 26 and as such the skilled person would not arrive at the claimed invention in view of the art cited either alone or in combination.

**CLAIMS 20 TO 25 ARE REJECTED UNDER OBVIOUSNESS-TYPE
NONSTATUTORY DOUBLE PATENTING**

Claims 20 to 23 stand rejected as unpatentable over claims 1-18 of U.S. Patent No. 6,264,994. Applicant submits that a terminal disclaimer will be timely filed once allowable subject matter is indicated.

Applicant believes it has responded fully to all of the concerns expressed by the Examiner in the Office Action. Applicant respectfully requests reexamination of new claim 26 and early favorable action on them. If the Examiner has any further concerns, Applicant requests an immediate call to Rebecca Eagen at (425) 823-0400 ext. 39.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Rebecca Eagen', with a large, stylized initial 'R'.

REBECCA EAGEN
Reg. No. L0386
PROTEOTECH, INC.
12040 115TH AVENUE N.E.
KIRKLAND, WA 98034